Navigation Links
Takeda's Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
Date:5/22/2008

SAN FRANCISCO, May 22 /PRNewswire/ -- Takeda San Francisco Inc. announced today the appointment of Mary Haak-Frendscho, Ph.D., as president and chief scientific officer. Dr. Haak-Frendscho will be responsible for leading all activities at Takeda San Francisco including overall research and preclinical development, process development studies and operations for antibody therapeutics.

Takeda San Francisco is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited of Osaka, Japan ("Takeda").

"Dr. Haak-Frendscho's strong leadership skills and biotechnology experience will greatly contribute to the success of Takeda San Francisco," said Shigenori Ohkawa, Ph.D., general manager, pharmaceutical research division, Takeda. "Takeda San Francisco will play an increasingly critical role in the expansion of Takeda's R&D capabilities as we look to promote the development of antibody therapeutics, and I am confident that Dr. Haak-Frendscho will help us realize our goals in the antibody field."

With more than 17 years of pharmaceutical and biotechnology experience, Dr. Haak-Frendscho has held positions at Genentech, Abgenix and most recently, at XOMA, where she served as chief science officer and vice president, preclinical research and development.

"I feel honored to join Takeda San Francisco," said Dr. Haak-Frendscho. "My background in biotechnology coupled with Takeda San Francisco's impressive existing antibody research is a natural fit, and will help realize Takeda's plan of creating new drugs through in-house R&D activities. I look forward to working with Takeda San Francisco's talented team to develop products that will improve the lives of patients."

Dr. Haak-Frendscho conducted post-doctorate work at the department of immunology, Genentech Inc., in preclinical in vitro and in vivo research and development of a humanized mAb therapeutic product candidate MaE11/MaE25 (Xolair(R)). She holds a doctorate in immunology from the University of Wisconsin-Madison and a master's in immunology from SUNY-Stony Brook. She received a Master of Liberal Arts from Washington University in St. Louis, and a Bachelor of Science in zoology from the University of Michigan-Ann Arbor.

Takeda San Francisco was established in November 2007 and supports Takeda's therapeutic antibody research aiming to build antibody technology platforms based on technologies such as discovery and development of antibodies, enhancement of antibody activity and antibody-manufacturing in close collaboration with Takeda's other R&D organizations.

About Takeda

Founded in 1781 and located in Osaka, Japan, Takeda (TSE: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product
2. ARIUS presents new findings for anti-cancer antibody programs at AACR
3. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
4. Antibody Engineering Company F-Star Buys Back Royalty Obligations
5. Genmab and PDL BioPharma Close Sale of Antibody Manufacturing Facility
6. Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK
7. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
8. Purchase Agreement for Antibody Manufacturing Facility Receives Antitrust Clearance
9. ESBATechs Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
10. Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility
11. Vaccinex Antibody Licensed to GlaxoSmithKline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... ... 2017 , ... Dr. Joshua Mondlick has introduced the LANAP® protocol to treat ... Perio, in the Phoenix area. Dr. Mondlick is at the forefront of the ... treatment to re-grow bone and with significantly less pain than traditional surgery options. , ...
(Date:7/14/2017)... USA/ Martinsried, Germany (PRWEB) , ... July 14, ... ... newly developed standardized solution for sample preparation of proteins to clean peptides for ... Diagenode Bioruptor® sonication system. , The PreOmics iST Kit is based on ...
(Date:7/13/2017)... ... July 13, 2017 , ... Heritage Biologics is ... is the independent leader in promoting healthcare quality through accreditation, certification and measurement. ... care, improved processes and better patient outcomes. , ÔÇťAchieving URAC accreditation is ...
(Date:7/13/2017)... ... 13, 2017 , ... FireflySci Inc. started manufacturing calibration standards ... years and now they are home to a tremendous line of certified calibration ... resolution testing. , One mega advantage that FireflySci brings to the ...
Breaking Biology Technology:
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):